Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Abraham N. Ceesay
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 84
- Beta
- 1.03
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 21.95
Financials
Revenue
$0.00-100.0%Net Income
$-56.62MEBITDA
$-56.40MFree Cash Flow
$-41.53MEPS (diluted)
$-1.19Shares Outstanding (diluted)
47.47M+144.0%Operating Expenses
$60.81MCash & Debt
$436.08MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-111.48M | $-2.86 |
| 2024 | $0.00 | $-78.31M | $-3.78 |
| 2023 | $0.00 | $-34.79M | $-0.95 |
| 2022 | $0.00 | $-10.65M | $-0.29 |
Valuation
RAPPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+200.00%Social Signal Score
Mentions (5)
- Newsbenzinga.com·7h ago·Neutral
Why Is Rapport Therapeutics Stock Trading Higher Today? Rapport Therapeutics Inc. (NASDAQ:RAPP) stock is trading higher on Tuesday with a premarket session volume of 1.439 million versus the average volume of 351.078 thousand, according to Benzinga Pro data.
View source ↗ - Newsbarrons.com·7h ago·Neutral
Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging Positive trial data for Rapport's lead pipeline candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 billion peak sales opportunity, Jefferies says.
View source ↗ - Newsglobenewswire.com·10h ago·Neutral
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania score (0.4 points; p=0.024)
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript
View source ↗ - Newsglobenewswire.com·48d ago·Neutral
Rapport Therapeutics to Participate in Upcoming Investor Conferences BOSTON and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor events: Cantor Global Healthcare Conf…
View source ↗
Earnings
Thu, Nov 5(in 2 weeks)
Consensus estimate $-1.20 per share
Typical surprise +8.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-1.19 vs $-0.96miss
- Thu, May 7$-0.42 vs $-0.56beat
- Tue, Mar 10$-0.72 vs $-0.65miss
- Thu, Nov 6$-0.71 vs $-0.77beat
- Thu, Aug 7$-0.75 vs $-0.87beat
- Thu, May 8$-0.68 vs $-0.77beat
Estimates and results for RAPP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RAPP officers and directors.
- Bought
- —
- Sold
- $49.7m
0 trades
80 trades
- Ceesay Abrahamsold
- Ceesay Abrahamsold
- Gault Cherylsold
- Gault Cherylsold
- Ceesay Abrahamsold
- Ceesay Abrahamsold
- Ceesay Abrahamsold
- Ceesay Abrahamsold
20 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RAPP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.